Dr Camille Carroll
Post Doctoral Research Fellow in Clinical Neuroscience
Clinical Trials & Health Research - Institute of Translational & Stratified Medicine (Plymouth University Peninsula Schools of M
Honorary Consultant Neurologist, Plymouth Hospitals NHS Trust
I undertook preclinical medical training at the University of Manchester, where I also completed an intercalated PhD (1994) under the supervision of Jon Brotchie and Ian Mitchell, investigating NMDA receptor antagonists in animal models of Parkinson's disease. I completed my clinical training at the University of Oxford in 1997, before undertaking junior medical positions in Oxford, Bath and London (including NHNN), gaining MRCP in 2000. I undertook my neurology specialist training in the South West and West Midlands Deaneries with posts in Plymouth, Bristol, Birmingham and Coventry. I entered the specialist register in Jan 2007.
Realising the importance and potential of molecular biology as a field that had developed enormously since my PhD, I was awarded an MRC clinical research training fellowship for post-doctoral students who need retraining in 2007. This has allowed me to develop research interests investigating neuroprotective mechanisms in cell culture models of Parkinson's disease. My current focus is on early disease detection and clinical trials of neuroprotective interventions in Parkinson's disease.
Roles on external bodies
I am Specialty Lead for Parkinson's disease in SWP CRN and also Division 2 Clinical Specialty Lead. I sit on the national Clinical Studies Group in Parkinson's disease. I am a member of the Question Writing Group (since 2005), Standard Setting Group (since 2007) and examining board (since 2015) for the Neurology SCE (RCP).
I have experience of behavioural pharmacology in animal models of Parkinson’s disease, and more recently have developed an interest in mechanisms of cell death and neuroprotective strategies. I have established a PD cell culture model which we utilize to investigate the neuroprotective effects of cannabinoids and endocannabinoid modulators, focusing on the intracellular downstream mechanisms mediating their effects. I have active collaborations locally and nationally investigating other aspects of PD pathogenesis including pre-symptomatic bowel alpha-synuclein expression, lysosomal pathways in Drosphila and verifying our cell culture findings in an in vivo mouse model. I currently co-supervise 2 PhD students and several placement students. I have previously contributed to studies of surgical intervention in Parkinson’s disease (PD), both in the UK and in the US, and planned and managed a clinical trial of cannabinoids for symptomatic therapy in PD. I am currently part of the NIHR-funded team investigating clinical trial methodology in neurodegenerative diseases, investigating outcome measures of various parameters in PD. I am joint PD research director for SW DeNDRoN and as such have responsibility for overseeing clinical research capability in the Peninsula and the development of a balanced clinical trial portfolio. I am PI on a number of clinical studies and have overseen the development of a PD DNA bank (1500 samples) and PD clinical research register.
Key publications are highlightedJournals